What's on this Page
Edetate Disodium (Disodium EDTA) Brand Names- Disotate | Endrate
What is Edetate Disodium (Disodium EDTA)
Edetate disodium a chelating agent with affinity for divalent and trivalent metals, is indicated in the treatment of hypercalcemia.
Because the drug can decrease blood calcium levels too rapidly (causing tetany, cardiac arrhythmias, and respiratory arrest), it now is only rarely used.
Due to its pharmacodynamic actions that oppose those of the cardiac glycosides, edetate disodium was once used to treat arrhythmias associated with digitalis toxicity, but digoxin immune Fab is now the preferred agent for this condition.
Edetate disodium should not be confused with its calcium salt (calcium EDTA), which is used to treat lead toxicity. In the 1950s and 1960s, edetate disodium was used for atherosclerotic vascular disease despite a lack of clinical data to support its efficacy.
Only 1 large, placebo-controlled, randomized, double-blind study has been conducted to evaluate this use of edetate disodium and this study showed no significant symptomatic or angiographic improvement in the EDTA group relative to placebo.
Nevertheless, there continues to be sustained interest in using this drug for the treatment of atherosclerosis.
Based on a recent clinical trial (PATCH), there is no evidence to support a benefit (evaluated exercise time to ischemia, exercise capacity, and quality of life measurements) of chelation therapy (Endrate®) in patients with ischemic heart disease including stable angina.
Because of the possibility of potentially lethal adverse effects, edetate disodium should not be used for the treatment of generalized arteriosclerosis due to advancing age.
Edetate disodium was approved by the FDA for clinical use in 1956.
Indications
- cardiac glycoside-induced arrhythmias
- hypercalcemia
For the treatment of hypercalcemia, or, for treatment of cardiac glycoside-induced arrhythmias (i.e., ventricular arrhythmias associated with digitalis toxicity)
Side Effects
- anemia
- diarrhea
- exfoliative dermatitis
- fever
- headache
- hyperuricemia
- hypocalcemia
- hypokalemia
- hypomagnesemia
- injection site reaction
- nausea
- orthostatic hypotension
- paresthesias
- phlebitis
- renal tubular necrosis
- vomiting
Monitoring Parameters
- serum creatinine/BUN
Contraindications
- anuria
- breast-feeding
- cardiac disease
- children
- diabetes mellitus
- geriatric
- heart failure
- hypocalcemia
- hypoglycemia
- hypokalemia
- hypomagnesemia
- hypotension
- intravenous administration
- pregnancy
- renal failure
- renal impairment
- seizure disorder
- tuberculosis
Interactions
- Calcium
- Calcium Acetate
- Calcium Carbonate
- Calcium Carbonate; Magnesium Hydroxide
- Calcium Carbonate; Risedronate
- Calcium Carbonate; Simethicone
- Calcium Chloride
- Calcium Gluconate
- Calcium; Vitamin D
- Carbetapentane; Guaifenesin; Phenylephrine
- Carbetapentane; Phenylephrine
- Cardiac glycosides
- Chlorpheniramine; Pseudoephedrine
- Chromium
- Digitoxin
- Digoxin
- Hetastarch; Dextrose; Electrolytes
- Insulins
- Magnesium
- Magnesium Citrate
- Magnesium Salts
- Succimer
- Zinc
- Zinc Salts